계명대학교 의학도서관 Repository

Choice between Levofloxacin and Moxifloxacin and Multidrug-Resistant Tuberculosis Treatment Outcomes

Metadata Downloads
Affiliated Author(s)
최원일
Alternative Author(s)
Choi, Won Il
Journal Title
Annals of the American Thoracic Society
ISSN
2329-6933
Issued Date
2016
Keyword
Multidrug-resistant tuberculosisFluoroquinolonesMoxifloxacinLevofloxacin
Abstract
Rationale: We previously showed that the choice of levofloxacin or
moxifloxacin for the treatment of patients with fluoroquinolone-sensitive
multidrug-resistant tuberculosis (MDR-TB) did not affect sputumculture
conversion at 3 months of treatment.
Objectives: To compare final treatment outcomes between patients
with MDR-TB randomized to levofloxacin or moxifloxacin.
Methods: A total of 151 participants with MDR-TB who were
included for the final analysis in our previous trial were followed
through the end of treatment. Treatment outcomes were compared
between 77 patients in the levofloxacin group and 74 in the
moxifloxacin group, based on the 2008 World Health Organization
definitions as well as 2013 revised definitions of treatment outcomes.
In addition, the time to culture conversion was compared between the
two groups.
Measurements and Main Results: Treatment outcomes were
not different between the two groups, based on 2008 World Health
Organization definitions as well as 2013 definitions. With 2008
definitions, cure was achieved in 54 patients (70.1%) in the
levofloxacin group and 54 (73.0%) in the moxifloxacin group
(P = 0.72). Treatment success rates, including cure and treatment
completed, were not different between the two groups (87.0 vs. 81.1%,
P = 0.38). With 2013 definitions, cure rates (83.1 vs. 78.4%, P = 0.54)
and treatment success rates (84.4 vs. 79.7%, P = 0.53) were also
similar between the levofloxacin and moxifloxacin groups. Time to
culture conversion was also not different between the two groups
(27.0 vs. 45.0 d, P = 0.11 on liquid media; 17.0 vs. 42.0 d, P = 0.14 on
solid media). Patients in the levofloxacin group had more adverse
events than those in the moxifloxacin group (79.2 vs. 63.5%, P = 0.03),
especially musculoskeletal ones (37.7 vs. 14.9%, P = 0.001).
Conclusions: The choice of levofloxacin or moxifloxacin made no
difference to the final treatment outcome among patients with
fluoroquinolone-sensitiveMDR-TB.
Clinical trial registered with www.clinicalrials.gov (NCT01055145).
Department
Dept. of Internal Medicine (내과학)
Publisher
School of Medicine
Citation
Young Ae Kang et al. (2016). Choice between Levofloxacin and Moxifloxacin and Multidrug-Resistant Tuberculosis Treatment Outcomes. Annals of the American Thoracic Society, 13(3), 364–370. doi: 10.1513/AnnalsATS.201510-690BC
Type
Article
ISSN
2329-6933
DOI
10.1513/AnnalsATS.201510-690BC
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/33147
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.